Newsroom

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced its participation at the 28th Annual American Society of Cell and Gene Therapy Meeting (ASGCT), taking place on May 13-17, 2025, in New-Orleans, United States of America. On this occasion, Rafik Boudra, Preclinical Group Leader Technology &...

NEWCASTLE UPON TYNE, England & PARIS--(BUSINESS WIRE)--Regulatory News:  Connected Energy et Forsee Power (FR0014005SB3 – FORSE) annoncent la signature d’un accord de partenariat visant à concevoir et développer conjointement une solution de stockage d’énergie modulaire et évolutive. Cette solution combinera la technologie éprouvée de seconde vie de Connected Energy avec les batteries ZEN 35 et ZEN 42 de Forsee Power, actuellement embarquées dans environ 1 500 bus électriques en Europe. L’accor...

NEWCASTLE UPON TYNE, England & PARIS--(BUSINESS WIRE)--Regulatory News: Connected Energy and Forsee Power (FR0014005SB3 – FORSE) have signed a Partnership Agreement to jointly design and develop a modular, scalable energy storage solution. This will combine Connected Energy’s proven second life technology with Forsee Power’s ZEN 35 and ZEN 42 battery packs, which are deployed in about 1,500 electric buses in Europe. Additionally, the agreement includes the development of an operating model to f...

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), société pionnière de biotechnologie au stade clinique, spécialisée dans le développement de nouvelles thérapies pour restaurer, traiter et prévenir les troubles de la perte auditive, annonce aujourd’hui sa participation à la 28ème conférence de la Société Américaine de Thérapie Génique et Cellulaire (ASGCT), qui se tiendra du 13 au 17 mai 2025, à la Nouvelle-Orléans, aux États-Unis d’Amérique. À cette occas...

LONDON & DENVER & JOHANNESBURG--(BUSINESS WIRE)--AngloGold Ashanti plc (“AngloGold Ashanti” or the “Company”) and Gold Fields have agreed to pause discussions about a proposed joint venture to combine their Iduapriem and Tarkwa gold mines in Ghana. The companies proposed the combination of the neighbouring mines in March 2023 and have spent much of the intervening time in a constructive dialogue with the Government of Ghana to obtain the necessary approvals. Over that time, AngloGold Ashanti ha...

SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”, NYSE ticker code: “BWLP”) will release its Q1 2025 Financial Report at approximately 07:00hrs CEST/ 01:00hrs EDT/ 13:00hrs SGT on 20 May 2025. In connection with this release, BW LPG will hold an Earnings Presentation with Kristian Sørensen (CEO) and Samantha Xu (CFO). The details are as following: Date: Tuesday, 20 May 2025 Location and Time: Oslo, Norway (14:00 CEST) New York, USA (08:00 EDT) Sin...

MONTREAL--(BUSINESS WIRE)--Innospera Pharma Inc. („Innospera“), ein privates Biotechnologieunternehmen im fortgeschrittenen klinischen Stadium, das sich auf die Entwicklung von niedermolekularen Modulatoren von GPR84 und GPR40 zur Behandlung einer Vielzahl von Entzündungs- und Stoffwechselerkrankungen mit hohem ungedecktem medizinischem Bedarf konzentriert, gab heute die Ernennung von François Ravenelle, PhD , zum Präsidenten und Chief Executive Officer mit sofortiger Wirkung bekannt. Dr. Raven...

MONTREAL--(BUSINESS WIRE)--Innospera Pharma Inc. ("Innospera"), società biotecnologica privata prossima alla fase clinica che si concentra sullo sviluppo di modulatori di piccole molecole dei recettori GPR84 e GPR40 per la cura di un ampio ventaglio di patologie infiammatorie e metaboliche non ancora trattate efficacemente, ha annunciato la nomina con effetto immediato di François Ravenelle in qualità di Presidente e CEO. Il dott. Ravenelle è un leader affermato in ambito biotech, che vanta olt...

MONTREAL--(BUSINESS WIRE)--Innospera Pharma Inc. («Innospera»), una empresa privada de biotecnología en fase casi clínica dedicada al desarrollo de moduladores de moléculas pequeñas de GPR84 y GPR40 para combatir una amplia gama de enfermedades inflamatorias y metabólicas con grandes deficiencias médicas, ha anunciado hoy el nombramiento del doctor François Ravenelle como presidente y director ejecutivo, con efecto inmediato. El Dr. Ravenelle es un reconocido líder del sector biotecnológico con...

BERLIN--(BUSINESS WIRE)--RSA, der führende Anbieter von Identitätslösungen, hat heute auf der European Identity and Cloud (EIC) Conference 2025 bahnbrechende Cybersecurity-Innovationen angekündigt, die Unternehmen vor der nächsten Welle von KI-gestützten Identitätsangriffen schützen, darunter Umgehungen des IT-Helpdesks, Malware, Social Engineering und andere Bedrohungen. Diese Fortschritte sind besonders wichtig für Organisationen, die passwortlose Strategien implementieren, und festigen die P...